Thus, imatinib may enhance CML cells to migrate to BM by increasing CXCR4 expression and block cell proliferation; BM stromal cells may protect and promote quiescent CML survival cells with potential implications for disease re-incidence [196,197]. Here, CXCR4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.